A minor subpopulation of CD4 + T cells that co-express the cell-surface molecule CD25 has emerged as the major population of T cells responsible for downregulation of the immune response and prevention of autoimmunity.
The late R.K. Gershon is usually credited with the conceptual discovery of suppressor T cells as that population of T cells specifically equipped to inhibit immune responses, including both antibody production by B lymphocytes and the activation of other T cells such as cytotoxic T cells. It was believed during much of the 1970s and early 1980s that suppressor T cells mediated their biological functions by producing antigen-specific soluble factors that bore determinants encoded by a specific region (termed I-J) of the murine major histocompatibility complex (MHC) and/or determinants encoded by immunoglobulin genes. The cloning of the genes encoding the T-cell receptor in the mid-1980s clearly demonstrated that the genes encoding the T-cell receptor were not identical to the immunoglobulin genes and other molecular studies failed to identify an I-J gene within the MHC. The field of T-cell-mediated suppression was left in disarray and most of the investigators who were active participants rapidly abandoned what was regarded as a sinking ship. Over the past 5-10 years, suppressor T cells have experienced somewhat of a revival. Here, I will review recent experimental evidence that has led us to regard suppressor T cells again as members of a separate lineage of cells that is responsible for downregulation of the immune response.
Rebirth
The experiments that reaffirm the existence and support the importance of suppressor T cells have come from studies involving the induction of organ-specific autoimmunity by manipulation of lymphocyte homeostasis. Two series of studies initiated more than 25 years ago formed the basis for the concept that depletion of regulatory T cells leads to the induction of autoimmunity. Removal of thymuses from mice on the third day of life was observed to lead to the development of a wide spectrum of organ-specific autoimmune disease [1] (Figure 1 ). The effector T cells responsible for the induction of disease were shown to express the CD4 coreceptor. Given that mice that were thymectomized on day 7 of life did not develop autoimmune disease, it was postulated that a population of regulatory T cells developed slightly later in ontogeny than the autoimmune effectors and that thymectomy on day 3 prevented the emigration of these regulatory cells to the peripheral lymphoid tissues. Indeed, autoimmune disease could be prevented by reconstitution of T cells in these mice either with a thymus transplant or by the injection of a suspension of normal CD4 + T cells from adult mice before day 14 of life.
One logical extension of the hypothesis put forth to explain this model is that autoreactive effectors and suppressors must co-exist in the normal adult animal and that removal of the suppressor population leads to the development of autoimmune disease. Strong support for this concept was derived from studies in the mid-1970s that demonstrated that thymectomy of adult rats ( Figure 1 ) that normally were resistant to the development of autoimmunity, followed by fractional doses of sublethal irradiation (to deplete peripheral lymphoid cells), resulted in the development of autoimmune thyroiditis [2] . Most importantly, the active role for regulatory T cells in this model was demonstrated by preventing the development of autoimmunity by reconstitution of the thymectomized, irradiated rats with lymphoid cells from normal donors after the final dose of irradiation.
Although these early experiments supported the existence of a population of unique regulatory cells, further progress was slow as it proved difficult to distinguish regulatory T cells from effector cells on the basis of the expression of unique membrane markers. Sakaguchi et al. [1] were the first to suggest that regulatory T cells could be separated from effectors on the basis of the relative expression of the Lyt-1 (CD5) antigen. The Lyt-1 antigen in the mouse is expressed on all T cells, however, and the suppressor cells were contained in the large (80%) subset of cells that express high levels of the Lyt-1 antigen. In the early 1990s, Mason's group was able to differentiate suppressors and effectors in the rat model on the basis of the differential expression of the RB isoform of the CD45 antigen. Subsequently, Powrie and Mason [3] extended this approach to the mouse and demonstrated that severe inflammatory bowel disease could be induced in immunodeficient mice that were injected with CD4 + CD45RB high T cells (Figure 1 ), while mice that received CD4 + CD45RB low T cells or a mixture of the two subsets never developed intestinal lesions [3] .
A major advance in the field was the demonstration by Sakaguchi et al. [4] in the mouse model that suppressor cells were exclusively present in the minor population (8-10%) of CD4 + T cells that co-express CD25, the interleukin-2 (IL-2) receptor α chain. Thus, transfer of CD4 + T cells from normal adult mice that had been depleted in vitro of the CD4 + CD25 + subset to immunodeficient recipients led to the development of a spectrum of autoimmune disease that resembled that seen after thymectomy at day 3 ( Figure 1 ). Transfer of the CD4 + CD25 + T cells within 10 days of transfer of the CD4 + CD25 -cells completely prevented the development of disease. Although CD45RB low cells do not all express CD25, Read et al. [5] have recently demonstrated that, in the CD45RB low population, it is only the CD4 + CD25 + subset that is responsible for the prevention of inflammatory bowel disease when cotransferred with CD45RB high cells.
Function
One of the major problems in studying the mechanism of suppressor T-cell function in vivo in autoimmunity models is that the assay systems are both indirect and complex as well as requiring weeks to months for the assessment of disease activity. In vitro model systems that potentially mimic the function of the suppressor cells in vivo have offered considerable insight. CD4 + CD25 + cells appear to be anergic when stimulated via their T-cell receptor or with IL-2 alone, yet they proliferate vigorously when stimulated with the combination of anti-CD3 antibodies and IL-2 [6] . These cells potently suppress the responses of CD4 + CD25 -T cells in co-culture experiments. The properties of this cytokine-independent, cell contact-dependent suppression are presented in Table 1 .
The role of suppressor cytokines in mediating the function of the CD4 + CD25 + cells in vivo is much more controversial. The protective effect of the CD45RB low suppressor population in the mouse inflammatory bowel disease model can be reversed by antibodies against the IL-10 receptor or against transforming growth factor β (TGFβ), while the protective effect of the rat CD45RB low cells in the thyroiditis model can be reversed by anti-IL-4 and anti-TGFβ antibodies [3] . In contrast, the suppressive effects of the CD4 + CD25 + T cells on the development of autoimmune gastritis cannot be reversed with antibodies against IL-4, IL-10 or TGFβ, and CD4 + CD25 + T cells from IL-4-and IL-10-deficient mice are also fully competent at mediating suppression [6] . It is possible that the CD4 + CD25 + population, upon appropriate activation in vivo, differentiates into subsets of suppressor effectors, some of which mediate suppression by a cell-contact-dependent mechanism, while others mediate suppression by secreting suppressor cytokines.
What is the cellular target for the suppressive activity of the CD4 + CD25 + T cells? If their activity is mediated by suppressor cytokines that function as deactivators of antigen-presenting cell function, then these cells are the logical target. Inhibition of antigen-presenting cell function would prevent the activation of the autoreactive effector population. A cell-contact-dependent mechanism of suppression could also target the antigen-presenting cell, but recent studies from my laboratory (reviewed in [6] ) do not support this view and we favor the possibility that the target of the CD4 + CD25 + suppressor is the responder CD4 + CD25 -T-cell population [7] . Dispatch R573 Table 1 Properties of CD4 + CD25 + T-cell-mediated suppression.
Requires activation of CD4 + CD25 + T cell [8] . Around 5% of CD4 + CD8 -thymocytes and less than 0.3% of CD4 -CD8 + thymocytes express the CD25 molecule. What is the physiological ligand recognized by the T-cell receptor of the CD4 + CD25 + T cells during thymocyte development and what is the ligand responsible for their activation in the periphery? My group has hypothesized that CD4 + CD25 + T cells are generated in the thymus during the process of negative selection. These cells bear T-cell receptors that are specific for selfantigens with intermediate affinity such that they are not deleted, yet not allowed to pass through to the periphery. The cells undergo a process we have termed 'altered negative selection', which results in a permanent change in their T-cell receptor signal transduction process, so that they leave the thymus in a partially incapacitated state and are precommitted to function as suppressor cells when they encounter their target antigen in the periphery [6] .
The possibility that the CD4 + CD25 + T cells recognize organ-specific antigens was originally proposed because the development of orchitis after thymectomy at day 3 could be inhibited by regulatory T cells from males, but not from females or orchiectomized males [1] . CD45RB low T cells from the peripheral lymphoid tissues of normal rats, but not rats lacking thyroid glands, are able to suppress thyroiditis induced by transfer of CD4 + CD45RB high T cells, while regulatory T cells from the thymus of athryoid animals are fully competent suppressors [9] . This result suggests that the development of the regulatory T cells in the thymus is normal, but that their maintenance or survival in the periphery requires the presence of the target antigen. Although it is not yet known whether the antigen responsible for their development in the thymus is related to their target antigen in the periphery, this possibility may indeed be the case because many supposedly 'organ-specific' antigens are also expressed in the thymus.
In addition to their specific target antigen, the other factor required for survival of the CD4 + CD25 + T cells is IL-2, because this population of cells is absent in IL-2-deficient mice [8] . As the CD4 + CD25 + T cells are incapable of producing IL-2, it is likely that they respond to low levels of IL-2 constitutively produced by CD25 -T cells. CD28-deficient mice have only half the number of CD4 + CD25 + cells -consistent with the view that the interaction of CD28 with its ligands CD80/CD86 is the major costimulatory signal needed for IL-2 production. One might therefore predict that blockade of the interaction of CD28 with its ligands might, in certain circumstances, lead to the development of autoimmunity. Salomon et al. [10] have recently reported that only 5-6% of CD4 + T cells in diabetes-prone non-obese diabetic (NOD) mice express CD25. When NOD mice are rendered deficient in either CD28 or in CD80/CD86, only 1-1.5% of the CD4 + T cells express CD25. Both of the deficient strains have an increased severity of autoimmune diabetes, which can be prevented by reconstitution with CD4 + CD25 + T cells from NOD donors. Thus, the exacerbation of diabetes in NOD mice deficient in CD80/CD86 or CD28 appears to be secondary to a deficiency in regulatory T cells.
A second intriguing feature of the CD4 + CD25 + T-cell population is that it is the only cell population in the normal mouse that appears to constitutively express cytotoxic T lymphocyte associated protein 4 (CTLA-4, also known as CD152) [5, 10, 11] . While CTLA-4 is structurally related to CD28 and interacts with the same ligands (CD80/CD86), it is widely accepted that triggering of CTLA-4 on activated T cells results in downregulation of T-cell activation rather than in costimulation. As expression of CTLA-4 is normally upregulated during the process of T-cell activation, it is possible that expression of CTLA-4 on the CD4 + CD25 + T cells is merely related to their partially activated phenotype which is induced during development of the CD4 + CD25 + cells in the thymus. Alternatively, CTLA-4 may play a role in the process of T-cell suppression.
Two observations support the latter possibility. First, suppression of inflammatory bowel disease mediated by CD25 + CD45RB low T cells was reversed by treatment of the animals with anti-CTLA-4 antibodies [5] . One explanation for this result is that the production of the critical suppressive cytokine needed for protection from inflammatory bowel disease, TGFβ, was blocked by the anti-CTLA-4 antibody treatment, because CTLA-4 triggering has been shown to result in the production of TGFβ (Figure 2) . Second, addition of anti-CTLA-4 antibody to co-cultures of mitogen-stimulated CD4 + CD25 + and CD4 + CD25 -T cells resulted in abrogation of the suppressive activity of the CD4 + CD25 + population [11] . TGFβ has been ruled out of playing any role in the suppression of lymphocyte proliferation in vitro in this particular model, but it is possible that ligation of CTLA-4 plays a role in costimulation of suppressor effector function (Figure 2) . One other study [12] that supports the role of CTLA-4 in the induction of suppression is that when immunodeficient mice are reconstituted with bone marrow containing CTLA-4-deficient T cells, they develop autoimmunity, whereas when they are reconstituted with a mixture of CTLA-4-deficient and normal cells, they show no signs of disease. Thus, the autoimmunity observed in CTLA-4-deficient mice is not due to a T-cell-autonomous defect and triggering of CTLA-4 on normal T cells leads to the induction of expression of a membrane molecule or secreted cytokine that downregulates the autoreactivity of the CTLA-4-deficient T cells.
Taken together, these papers suggest that CTLA-4 may have a critical role in some of the steps required for induction of regulatory T cell function. If further studies confirm that the interaction of CD80/CD86 with CTLA-4 is required for activation of regulatory T cells, these results will have profound implications for ongoing clinical trials investigating the use of anti-CD80/CD86 reagents for the therapy of autoimmune disease. Blockade of regulatory T cell functions may result in harmful rather than beneficial effects.
